Clinical Trials

Phase 2 Active not recruiting

Leukemia, Plasma Cell

NCT01446133 2026-01-27

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02312102 2026-01-16

Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

MyeloidOther hematologic neoplasm

22 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01496976 2025-12-19

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

45 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

250 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02005289 2025-12-15

Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

41 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT06517017 2025-11-28

UltraFrailMM

Phase 2 Recruiting

40 enrolled

Leukemia, Plasma Cell, Multiple Myeloma

NCT02568553 2025-11-26

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

35 enrolled

Phase 2 Active not recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01351896 2025-11-20

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

49 enrolled 34 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01995669 2025-06-24

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Phase 1/2 Completed

66 enrolled 13 charts

Phase 1 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02334865 2025-05-11

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

18 enrolled

Leukemia, Plasma Cell, Multiple Myeloma

NCT01729091 2025-05-09

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

72 enrolled 14 charts

Leukemia, Plasma Cell, Multiple Myeloma

NCT00848328 2025-04-24

Lenalidomide and Rituximab in Treating Patients With Non-Hodgkin Lymphoma

Phase 2 Terminated

30 enrolled

Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

8 enrolled

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05828459 2025-03-20

First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors

Phase 1 Recruiting

150 enrolled

Phase 1/2 Enrolling by invitation

Hematologic Neoplasms

NCT06762431 2025-01-07

VTB-CLL002

60 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

LymphoidOther hematologic neoplasmPlasma cell

41 enrolled 11 charts

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT01199575 2024-08-15

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

30 enrolled 12 charts

Phase 1 Active not recruiting

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06547944 2024-08-09

ZGR in TN CLL

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02843074 2023-12-05

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

53 enrolled 14 charts

Multiple Myeloma, Hematologic Neoplasms

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Hematologic Neoplasms

NCT01772420 2023-07-27

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Classical hematologyOther hematologic neoplasm

52 enrolled 21 charts

Anemia, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelomonocytic, Chronic

NCT01754857 2023-06-27

Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL

36 enrolled 11 charts

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02280525 2023-06-07

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

8 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00602459 2023-05-22

Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

418 enrolled 15 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00783367 2023-03-30

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

50 enrolled 11 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02225275 2022-09-28

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Terminated

9 enrolled 9 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

NCT03379051 2022-08-22

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Phase 1/2 Terminated

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01241786 2022-07-20

VZCLLPI0146

Phase 2 Terminated

5 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01744912 2022-05-11

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Phase 1 Terminated

10 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04490707 2022-03-24

Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML

Phase 3 Unknown

60 enrolled

Leukemia, Myeloid, Acute

NCT01433965 2022-03-10

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

MyeloidOther hematologic neoplasm

16 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00352365 2022-02-11

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia

41 enrolled 11 charts